Skip to content
New issue

Have a question about this project? Sign up for a free GitHub account to open an issue and contact its maintainers and the community.

Sign up for GitHub

By clicking “Sign up for GitHub”, you agree to our terms of service and privacy statement. We’ll occasionally send you account related emails.

Already on GitHub? Sign in to your account

Update vaccin status #312

Open
wants to merge 1 commit into
base: main
Choose a base branch
from
Open

Update vaccin status #312

Changes from all commits
Commits
Show all changes
1 commit
Select commit
File filter

Filter by extension

Filter by extension
Conversations
Failed to load comments.
Loading
Jump to
Jump to file
Failed to load files.
Loading
Diff view
Diff view
36 changes: 23 additions & 13 deletions src/VaccinTracker/autorisations.php
View file
Open in desktop
Original file line number Diff line number Diff line change
Expand Up @@ -59,10 +59,16 @@
Statut : vaccin en <a target="_blank" href="https://www.ema.europa.eu/en/news/ema-starts-rolling-review-sputnik-v-covid-19-vaccine">cours d'évaluation</a> par l'AEM<br>
<a target="_blank" title="Sputnik V COVID-19 vaccine candidate appears safe and effective" href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00191-4/fulltext">Article</a>
</card>
</div>

<h3 style="margin-top : 50px;">Vaccins non encore soumis</h3>
<div class="row">
<card class="shadow-btn-red col-xs-11 col-md-4"><b>🇺🇸 Novavax</b><br>
Phase 3/3<br>
Type : Sous-unité protéique<br>
Efficacité annoncée : 89,3%<br>
Conservation : entre +2°C et +8°C<br>
Commandes UE : 100M (+ option 100M)<br>
Dont France : 15M (+ option 15M)<br>
Doses à injecter : 2<br>
Statut : vaccin en <a target="_blank" href="https://www.ema.europa.eu/en/news/ema-starts-rolling-review-novavaxs-covid-19-vaccine-nvx-cov2373">cours d'évaluation</a> par l'AEM<br>
</card>
<card class="shadow-btn-red col-xs-11 col-md-4"><b>🇩🇪 CureVac</b><br>
Phase 2/3<br>
Type : ARN messager<br>
Expand All @@ -72,20 +78,24 @@
Commandes UE : 225M (+ option 180M)<br>
Dont France : 33.75M (+ option 27M)<br>
Doses à injecter : 2<br>
Statut : examen continu (UE)
Statut : vaccin en <a target="_blank" href="https://www.ema.europa.eu/en/news/ema-starts-rolling-review-curevacs-covid-19-vaccine-cvncov">cours d'évaluation</a> par l'AEM<br>
</card>

<card class="shadow-btn-red col-xs-11 col-md-4"><b>🇺🇸 Novavax</b><br>
</div>
<div class="row">
<card class="shadow-btn-orange col-xs-11 col-md-4"><b>🇨🇳 Sinovac Life Sciences</b><br>
<i>Ce vaccin n'a pas été pré-commandé par l'UE</i><br>
Phase 3/3<br>
Type : Sous-unité protéique<br>
Efficacité annoncée : 89,3%<br>
Type : Vaccin inactivé<br>
Efficacité annoncée : 83,5%<br>
Prêt : oui<br>
Conservation : entre +2°C et +8°C<br>
Commandes UE : 100M (+ option 100M)<br>
Dont France : 15M (+ option 15M)<br>
Doses à injecter : 2<br>
Statut : examen continu (UE)
Statut : vaccin en <a target="_blank" href="https://www.ema.europa.eu/en/news/ema-starts-rolling-review-covid-19-vaccine-vero-cell-inactivated">cours d'évaluation</a> par l'AEM<br>
</card>

</div>

<h3 style="margin-top : 50px;">Vaccins non encore soumis</h3>
<div class="row">
<card class="shadow-btn-red col-xs-11 col-md-4"><b>🇫🇷🇬🇧 Sanofi/Pasteur-GSK</b><br>
Phase 2/3<br>
Type : Protéines virales<br>
Expand Down